Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of November 2024. The filing, dated November 11, 2024, serves primarily to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for the attached press release rather than a standalone financial statement.
Material Changes
No material financial changes versus prior periods are detailed within the body of this Form 6-K. The filing indicates that material information is contained in the referenced press release, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing does not contain explicit guidance, management commentary, risk factors, or details on contingencies. These elements are presumed to be addressed in the incorporated press release (Exhibit 99.1), which is not present in the source text.
Key Facts for Investor Verification
- Verify the content of the press release dated November 11, 2024 (Exhibit 99.1), as this filing incorporates it by reference.
- Confirm the specific nature of the announcement, as the Form 6-K text itself contains no operational or financial details.
- Note that the registrant is a foreign private issuer subject to Form 20-F reporting requirements.